However, for patients with tumor ≤5 cm, the 1, 3, 5-year overall survival for patients with HMGB1 high expression was 91.7%, 68.9%, 48.5% respectively, and 91.8%, 81.2%, 69.8% respectively for patients with HMGB1 low expression (p = 0.101), and the corresponding disease-free survival was 61.1%, 41.7%, 27.5% respectively, and 76.7%, 56.9%, 45.1% respectively (p = 0.087, Figure 4). Here, HMGB1 is linked to neoplasm.